2013
Treatment of Stage III Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA, Diekemper R, Detterbeck FC, Arenberg DA. Treatment of Stage III Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST Journal 2013, 143: e314s-e340s. PMID: 23649445, DOI: 10.1378/chest.12-2360.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerLung cancerDefinitive chemoradiationNeoadjuvant therapyStage IIIARandomized trialsPractice guidelinesAmerican CollegeChest Physicians Evidence-Based Clinical Practice GuidelinesEvidence-based clinical practice guidelinesNon-small cell lung cancer diagnosisLow perioperative mortality ratePlatinum-based adjuvant chemotherapyStage IIIA lung cancerStage III lung cancerCell lung cancer diagnosisIIIA lung cancerMicroscopic nodal metastasesProphylactic cranial radiationChest Physicians guidelinesPerioperative mortality rateCell lung cancerClinical practice guidelinesStrength of recommendationsLung cancer diagnosis
2012
Benefits and Harms of CT Screening for Lung Cancer: A Systematic Review
Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T, Colditz GA, Gould MK, Jett JR, Sabichi AL, Smith-Bindman R, Wood DE, Qaseem A, Detterbeck FC. Benefits and Harms of CT Screening for Lung Cancer: A Systematic Review. JAMA 2012, 307: 2418-2429. PMID: 22610500, PMCID: PMC3709596, DOI: 10.1001/jama.2012.5521.Peer-Reviewed Original ResearchConceptsLow-dose computed tomographyLung cancer mortalityLung cancerLDCT screeningCancer deathCancer mortalityEffect of LDCTSystematic reviewNational Lung Screening TrialEvidence-based clinical guidelinesFrequency of followLung cancer deathsLung cancer screeningRisk of deathPotential harmAdvanced diseaseCause mortalityCohort studyMost patientsSecondary outcomesMajor complicationsPrimary outcomeRandomized studyRandomized trialsCT screening
2009
Thoracoscopic versus open lobectomy debate: the pro argument
Detterbeck F. Thoracoscopic versus open lobectomy debate: the pro argument. Thoracic Surgical Science 2009, 6: doc04. PMID: 21289905, PMCID: PMC3011293, DOI: 10.3205/tss000018.Peer-Reviewed Original ResearchVATS lobectomyLung cancerLarge randomized trialsConfidence intervalsRate of deathAbility of patientsLong-term survivalAdjuvant chemotherapyForrest plotsMajor bleedingMinor endpointsPulmonary complicationsPostoperative painBlood transfusionOperative timeRandomized trialsLess painMediastinal stagingOpen lobectomyFunctional outcomeTumor stageNodal stationsClinical trialsOdds ratioLobectomy
2004
Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer
Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, Hensing TA, Socinski MA. Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer. Journal Of Clinical Oncology 2004, 22: 4837-4845. PMID: 15570087, DOI: 10.1200/jco.2004.01.178.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantCombined Modality TherapyConfidence IntervalsDose Fractionation, RadiationDose-Response Relationship, RadiationHumansLung NeoplasmsNeoplasm StagingOdds RatioPneumonectomyPrognosisRadiotherapy DosageRadiotherapy, AdjuvantRandomized Controlled Trials as TopicRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsThoracic radiation therapyPlatinum-based chemotherapyRisk ratioRadiation therapyLS-SCLCLung cancerLimited-stage small cell lung cancerSmall cell lung cancerHyperfractionated radiation therapyLimited-Stage SmallProphylactic cranial irradiationCombined modality therapyCell lung cancerCranial irradiationChemotherapy regimensChemotherapeutic regimenModality therapySurvival benefitRandomized trialsDaily fractionationSubset analysisRadiation fractionationRT relativeRisk differenceChemotherapy